公开(公告)号：US10716787B2

公开(公告)日：2020-07-21

申请号：US15955149

申请日：2018-04-17

Applicant: ASTEX THERAPEUTICS LTD

Inventor： Eleonora Jovcheva ,  Timothy Pietro Suren Perera

IPC: A61K31/4985 ,  A61K31/5025 ,  A61K31/498 ,  A61K45/06

Abstract: The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor.The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer.The FGFR inhibitor (N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof) and the cMet inhibitor can be administered simultaneously, separately or sequentially.The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.

公开(公告)号：US11918576B2

公开(公告)日：2024-03-05

申请号：US16931728

申请日：2020-07-17

Applicant: ASTEX THERAPEUTICS LTD

Inventor： Eleonora Jovcheva ,  Timothy Pietro Suren Perera

IPC: A61K31/4985 ,  A61K31/498 ,  A61K31/5025 ,  A61K45/06

CPC classification number: A61K31/4985 ,  A61K31/498 ,  A61K31/5025 ,  A61K45/06 ,  A61K31/498 ,  A61K2300/00 ,  A61K31/4985 ,  A61K2300/00 ,  A61K31/5025 ,  A61K2300/00

Abstract: The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor.
The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer.
The FGFR inhibitor (N-(3,5-dimethoxyphenyl)-N-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof) and the cMet inhibitor can be administered simultaneously, separately or sequentially.
The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.

公开(公告)号：US10736900B2

公开(公告)日：2020-08-11

申请号：US15128347

申请日：2015-03-26

Applicant: ASTEX THERAPEUTICS LTD

Inventor： Eleonora Jovcheva ,  Timothy Pietro Suren Perera

IPC: A61K31/53 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/519

Abstract: The invention relates to a combination of a FGFR inhibitor and an IGF1R inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer. The FGFR inhibitor and the IGFR inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.

公开(公告)号：US10085982B2

公开(公告)日：2018-10-02

申请号：US15128342

申请日：2015-03-26

Applicant: ASTEX THERAPEUTICS LTD

Inventor： Eleonora Jovcheva ,  Timothy Pietro Suren Perera

IPC: A61K31/498 ,  A61K31/4985 ,  A61P35/00 ,  A61K45/06

Abstract: The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer. The FGFR inhibitor (N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof) and the cMet inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.